Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor.

J Pharmacol Exp Ther

Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn, Bonn, Germany (W.K.S., R.S., J.E., T.B., A.B., K.M.); Institute of Physiology I, Life&Brain Center, Medical Faculty, University of Bonn, Bonn, Germany (D.W., P.S., B.K.F.); Institute of Pharmacology & Toxicology, University of Bonn, Bonn, Germany (M.W., E.S., K.R.); Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Würzburg, Würzburg, Germany (J.K., U.H.); Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica 'Pietro Pratesi,' Università degli Studi di Milano, Milano, Italy (M.D.); Molecular, Cellular, and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn, Bonn, Germany (E.K.); Institute of Physiology II, University of Bonn, Bonn, Germany (R.M.); Center of Pharmacology, University of Cologne, Cologne, Germany (W.K.S.).

Published: February 2017

AI Article Synopsis

  • Drug discovery is focused on creating selective ligands for targeted tissue modulation, aiming for safer drug actions.
  • The study introduces engineered context-sensitive agonism as a potential solution to reduce unwanted side effects, particularly in relation to heart rate slowdown caused by acetylcholine M-receptor activation.
  • Dualsteric agonists were found to cause less cardiac depression than traditional full agonists, utilizing a mechanism that allows for partial agonism via elevation of intracellular cAMP levels, thus improving tissue selectivity in drug actions.

Article Abstract

Drug discovery strives for selective ligands to achieve targeted modulation of tissue function. Here we introduce engineered context-sensitive agonism as a postreceptor mechanism for tissue-selective drug action through a G protein-coupled receptor. Acetylcholine M-receptor activation is known to mediate, among other actions, potentially dangerous slowing of the heart rate. This unwanted side effect is one of the main reasons that limit clinical application of muscarinic agonists. Herein we show that dualsteric (orthosteric/allosteric) agonists induce less cardiac depression ex vivo and in vivo than conventional full agonists. Exploration of the underlying mechanism in living cells employing cellular dynamic mass redistribution identified context-sensitive agonism of these dualsteric agonists. They translate elevation of intracellular cAMP into a switch from full to partial agonism. Designed context-sensitive agonism opens an avenue toward postreceptor pharmacologic selectivity, which even works in target tissues operated by the same subtype of pharmacologic receptor.

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.116.237149DOI Listing

Publication Analysis

Top Keywords

context-sensitive agonism
16
engineered context-sensitive
8
tissue-selective drug
8
protein-coupled receptor
8
agonism
5
agonism tissue-selective
4
drug signaling
4
signaling protein-coupled
4
receptor drug
4
drug discovery
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!